Integral Molecular announces new patent protecting use of lipoparticles for …News-Medical.netIntegral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent protecting the use of Lipoparticles for eliciting…
|
Company Update: Biogen Idec Inc (NASDAQ:BIIB) – US FDA approves Biogen’s …
Jutia Group Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical … |
|
Halozyme: European Approval Of Roche’s MabThera SC For Non-Hodgkin …
NASDAQ (RTTNews.com) – Halozyme Therapeutics Inc ( HALO ) said Friday the European Commission has approved Roche’s ( RHHBY ) new subcutaneous formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large … |
|
Stocks Alert: Halozyme Therapeutics, Inc. (NASDAQ:HALO), EXACT Sciences …
Market News Call 28 announced that the European Commission (EC) has approved Roche’s new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of … |
|
Pre-market Gainers: BofI Holding, Inc. (NASDAQ:BOFI), Hansen Medical, Inc …
Gaining Green Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that the European Commission (EC) has approved Roche’s new subcutaneous (SC) formulation of MabThera® (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell … |
Drug Discovery & Development |
Roche nabs European approval for time-saving formulation of Rituxan
FiercePharma Swiss pharma giant Roche ($RHHBY) is pursuing that game plan for some of its hit biotech drugs–and today it scored a victory when European regulators approved a subcutaneous version of its cancer drug Rituxan (rituximab), known as MabThera overseas. Europe OKs New Formula of Roche Cancer DrugDrug Discovery & Development Halozyme Platform Wins EC Approval for Roche’s MabThera SCGenetic Engineering News EC approves Roche’s SC formulation of MabThera for common forms of non …News-Medical.net NASDAQ –Wall Street Journal all 12 news articles » |
Drug Discovery & Development |
EC approves Roche’s SC formulation of MabThera for common forms of non …
News-Medical.net Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche’s new subcutaneous (SC) formulation of MabThera® (rituximab) for the treatment of patients with follicular lymphoma and diffuse large … Europe OKs New Formula of Roche Cancer DrugDrug Discovery & Development Halozyme Platform Wins EC Approval for Roche’s MabThera SCGenetic Engineering News Halozyme: European Approval Of Roche’s MabThera SC For Non-Hodgkin …NASDAQ SYS-CON Media (press release) all 15 news articles » |
|
Europa aprueba ‘MabThera’ (rituximab) subcutáneo para el tratamiento del …
infosalus.com La Comisión Europea ha aprobado el uso de la formulación subcutánea (SC) de rituximab, comercializado por Roche con el nombre de ‘MabThera’, para el tratamiento de las clases de linfoma no Hodgkin (LNH) más frecuentes. Tras la aprobación de … |
Redacción Médica |
Europa aprueba ‘MabThera’ (rituximab) subcutáneo para el tratamiento del …
Te Interesa La Comisión Europea ha aprobado el uso de la formulación subcutánea (SC) de rituximab, comercializado por Roche con el nombre de ‘MabThera’, para el tratamiento de las clases de linfoma no Hodgkin (LNH) más frecuentes. Tras la aprobación de … Europa da luz verde a MabThera, de Roche, por la vía subcutáneaRedacción Médica |
|
Europa aprueba ‘MabThera’ (rituximab) subcutáneo para el tratamiento del …
TeleCinco.es La Comisión Europea ha aprobado el uso de la formulación subcutánea (SC) de rituximab, comercializado por Roche con el nombre de ‘MabThera’, para el tratamiento de las clases de linfoma no Hodgkin (LNH) más frecuentes. Tras la aprobación de … |